Prognose

Das durchschnittliche Kursziel der Analysten beträgt +63,74€(+680.882,91%). Der Median liegt bei +63,74€(+680.882,91%).

Kaufen	2
Halten	0
Verkaufen	1

Scoring-Modelle

Dividenden-Strategie	0 / 15
HGI-Strategie	7 / 18
Levermann-Strategie	-1 / 13

Beliebteste Broker

News

Evofem Biosciences Announces Financial Results for the Third Quarter of 2024
— Improved loss from operations by 31% — — Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections — — Forged commercial agreement for Phexxi in Middle East — SAN DIEGO , Nov. 14, 2024 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB: EVFM) today announced financial results for the third quarter and nine-month period ended September 30, 2024. Highlights include: Acquired global rights to SOLOSEC® (secnidazole) 2g oral granules, a single-dose oral antibiotic FDA approved to treat bacterial vaginosis and trichomoniasis, two common sexual health infections.» Mehr auf prnewswire.com
Evofem Secures Investor Support for Proposed Merger through Voting Agreements
SAN DIEGO , Nov. 6, 2024 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) ("Evofem" or the "Company") today announced it has secured voting agreements with certain of its Series E-1 stockholders and convertible noteholders to ensure they will vote in favor of the proposed merger with Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt") subsidiary Adifem, Inc., under the Amended and Restated Merger Agreement, as amended (the "A&R Merger Agreement), at Evofem's upcoming Special Meeting of Stockholders (the "Meeting"). Under the voting agreements, certain holders of Evofem's Series E-1 Convertible Preferred Stock have agreed to vote the voting power of their shares, and certain holders of Evofem's Convertible Notes have agreed to vote any EVFM common stock they hold as of the record date for the Special Meeting, in favor of the merger proposal.» Mehr auf prnewswire.com
Evofem Biosciences Addresses the Impact of GLP-1 Medications on Oral Contraceptive Absorption and Introduces Phexxi as a Non-Oral Solution
SAN DIEGO , Aug. 20, 2024 /PRNewswire/ -- As the popularity of GLP-1 receptor agonists continues to surge in the treatment of obesity and type 2 diabetes, Evofem Biosciences, Inc. (OTCQB: EVFM) is raising awareness of the potential impact these medications may have on the effectiveness of oral contraceptives. With an increasing number of women turning to GLP-1 medications for weight management and glycemic control, the need for reliable non-oral contraceptive options has never been more acute.» Mehr auf prnewswire.com

Unternehmenszahlen

Im letzten Quartal hatte Evofem Biosciences einen Umsatz von 4,04 Mio€ und ein Nettoeinkommen von −2,12 Mio€

(EUR)	Sep. 2024	YOY
Umsatz	+4,04 Mio	16,39%
Bruttoeinkommen	+3,26 Mio	6,98%
Nettoeinkommen	−2,12 Mio	103,41%
EBITDA	−2,19 Mio	34,01%

Fundamentaldaten

Metrik	Wert
Marktkapitalisierung	+946,00k€
Anzahl Aktien	100,33 Mio
52 Wochen-Hoch/Tief	+0,22€ - +0,00577€
Dividenden	Nein
Beta	-0,78
KGV (PE Ratio)	−0,12
KGWV (PEG Ratio)	0,00
KBV (PB Ratio)	−0,01
KUV (PS Ratio)	+0,06

Unternehmensprofil

Evofem Biosciences, Inc. ist ein biopharmazeutisches Unternehmen, das verschiedene Produkte entwickelt und vermarktet, um ungedeckte Bedürfnisse im Bereich der sexuellen und reproduktiven Gesundheit von Frauen zu erfüllen. Sein kommerzielles Produkt ist Phexxi, ein Vaginalgel zur Verhütung von Schwangerschaften. Das Unternehmen ist auch an der Entwicklung von EVO100 beteiligt, einem antimikrobiellen Vaginalgel zur Prävention der urogenitalen Übertragung von Chlamydia trachomatis und Neisseria gonorrhoeae bei Frauen. Der Hauptsitz von Evofem Biosciences, Inc. befindet sich in San Diego, Kalifornien.